Mahuad, C. V., Repáraz, M. d. l. Á. V., Zerga, M. E., Aizpurua, M. F., Casali, C., & Garate, G. (2016). Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib. Rare Tumors.
Citação norma ChicagoMahuad, Carolina Valeria, María de los Ángeles Vicente Repáraz, Marta E. Zerga, María Florencia Aizpurua, Claudia Casali, and Gonzalo Garate. "Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated With Crizotinib." Rare Tumors 2016.
MLA citiranjeMahuad, Carolina Valeria, et al. "Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated With Crizotinib." Rare Tumors 2016.